The efficacy of cellular immune responses elicited by HIV vaccines is dependent on their strength, durability and antigenic breadth. The regulatory proteins are abundantly expressed early in the viral life cycle and CTL recognition may bring about early killing of infected cells. We synthesised DNA vaccine constructs that encode consensus HIV-1 subtype C Tat, Rev and Nef proteins. Proteins carrying inactivating mutations were tested for functional activity and highly expressing, inactive Tat, Rev and Nef mutants were identified and their reading frames fused into a TatRevNef cassette. Single-and polygene Tat, Rev and/or Nef constructs were immunogenic in BALB/c mice. These constructs may serve to increase the antigenic breadth for an HIV-1 vaccine that is relevant for subSaharan Africa.
, [5] , [6] , [7] and [8] and are inversely correlated with disease progression [9] . Moreover, strong and cross-reactive CTL responses have been associated with resistance to HIV-1 infection in highly exposed, seronegative commercial sex workers in Kenya and the Gambia [10] , [11] and [12] . However, the identification of viruses that escape from CTL and thus evade the immune system [13] and [14] has highlighted the need for such vaccine-elicited CTL responses to recognize an array of epitopes from multiple HIV-1 antigens. An effective HIV-1 vaccine may thus require strong humoral and cellular immune responses to multiple viral antigens including structural and regulatory proteins.
The regulatory proteins Tat, Rev and Nef are expressed early during the viral life cycle [15] and CTL recognition of these antigens may effect killing of infected cells prior to completion of the viral life cycle and mature virion production [16] and [17] . Tat, Rev and/or Nef-specific immune responses have been demonstrated to correlate with nonprogression or even protection from disease [14] , [18] , [19] and [20] . However, these proteins perform intrinsic functions that may raise safety and suitability concerns when introduced as vaccines. Tat acts as viral transactivator and has a number of effects on cells such as upregulation of chemokine receptor expression [21] and overproduction of interferon-α [22] . The Rev protein regulates viral gene expression by mediating nuclear export of incompletely spliced viral RNAs [23] . Nef acts on a great number of cellular pathways and effects a multitude of alterations that collectively seem to provide an optimal environment for viral replication. These include increasing virion infectivity [24] , downregulation of cell surface CD4 [25] and MHC-I [26] expression and interference of T cell transduction and activation through numerous complex interactions (reviewed in reference [27] ).
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A large number of studies have served to identify inactivating mutations and functional domains of the regulatory proteins Tat, Rev and Nef. Consequently, numerous immunogens and therapeutic agents based on mutated Tat, Rev and Nef have been developed and in some cases have shown to be promising. The inactivation of Tat by mutation of cysteine residues at positions 22, 25, 27 and 37 was first shown by Garcia et al. [28] and Ruben et al. [29] and TatC22 has since been developed as prophylactic and/or therapeutic vaccine [30] , [31] and [32] . Similarly, two inactivating mutations termed M5 and M10 were identified in the Rev protein by Malim et al. [33] . RevM10 has since been developed as gene therapy agent and was shown to be clinically safe in human trials [34] and [35] . While Nef has also been shown to be a promising vaccine component, studies have demonstrated that inactivity of its intrinsic functions are abrogated in Nef proteins lacking myristoylation [36] or carrying, among a number of other mutations, the D123G [37] and LL165AA [38] and [39] mutations. Notably, to our knowledge, all mutational analysis of Tat, Rev and Nef has been done on proteins encoded by subtype B viruses.
As candidate components of a multipronged prime-boost vaccine strategy, we designed and synthesised codon-optimized DNA plasmid constructs that encode South African HIV-1 subtype C consensus Tat, Rev and Nef proteins. As these previous functional studies have been conducted on subtype B gene sequences, it was important to determine whether previously described inactivating mutations were applicable to similar gene constructs based on subtype C sequences. Thus, these genes were mutated to abrogate their respective undesirable protein activities and tested for functional inactivity to identify candidate subtype C Tat, Rev and Nef immunogens. In addition, immunogenicity of mutated, codon-optimized gene constructs was compared to the immunogenicity of wild-type functional genes in a mouse model.
Materials and methods

Vaccine strain selection openUP -May 2007
We previously isolated and characterized 15 HIV-1 subtype C isolates from South Africa   designated TV001 through TV010, TV012-TV014, TV018 and TV019 [40] , [41] , [42] , [43] and [44] . The Tat, Rev and Nef amino acid sequences of 14 of these 15 subtype C isolates were used to derive respective consensus sequences (designated TV Cons) by taking the most prevalent residue for each amino acid position across the reading frames of the three regulatory proteins. Amino acid distances were calculated with the Kimura distance matrix [45] using the Phylip program PROTDIST.
Expression plasmid construction
Wild-type tat, rev and nef genes encoding proteins that most closely resemble the amino acid sequences of the respective TV Cons sequences (tat: TV019, rev: TV010, nef:
TV002) were PCR amplified and cloned over SalI (XhoI for nef) and EcoRI sites into the pCMVKm2 plasmid vector as described previously [46] . The second exon of tat and first exon of rev were assembled from synthetic oligomers and cloned in-frame with the amplified exons over the KpnI and AvrII sites, respectively. Codon-optimized, synthetic gene constructs encoding the consensus TV Cons Tat, Rev and Nef sequences were also made by PCR assembly of 50mer oligonucleotides and cloned into the pCMVKm2 vector over SalI and EcoRI sites. Optimized initiation and termination codon contexts were also employed in these plasmid constructs [47] and [48] . Mutations (Table 1) 
Functionality assays
Tat functionality was assayed as described by Kuppuswamy et al. [49] . Briefly, 293T and HeLa cells were co-transfected with 1 µg pLTR-CAT reporter plasmid [50] , 1 µg tat expression plasmid and 0.5 µg pSV-βGal internal control plasmid (Promega, Madison, WI, USA) as described above. Cell lysates were harvested 24 h post-transfection and CAT enzyme levels were determined using a CAT ELISA as directed by the manufacturer (Roche Diagnostics, GmbH, Germany).
Rev functionality was determined in a cotransfection assay first described by Hope et al. [51] . One microgram of the pDM128 reporter plasmid (kindly donated by Prof. Thomas
Hope) was co-transfected with 1 µg rev expression plasmid and 0.5 µg pSV-βGal internal control plasmid. Cell lysate harvesting was performed as described for Tat.
The CD4 and MHC-I downregulation functions of Nef were assessed in a cotransfection assay adapted from the one described by Goldsmith et al. [52] . Briefly, 293 cells were co- 
Statistical Analysis
The paired t-test was performed using GraphPad Prism version 3.0a software.
Differences were considered statistically significant when p ≤ 0.05.
Immunogenicity studies
Six to eight-week-old female BALB/c mice were immunized at weeks 0 and 4 with 0. 
Results
Consensus sequences as vaccine strains
To select a vaccine strain that will exhibit a minimum genetic distance to currently circulating viruses, amino acid distances were calculated for individual viral isolate sequences from a panel of 14 tat, rev and nef sequence-characterized HIV-1 subtype C isolates versus the remaining 13 isolate sequences. Similarly, the distances between the consensus sequence drawn up from these isolates (designated TV Cons) and the 14 isolate sequences were calculated and the averages of these distances for each regulatory protein are plotted in Fig. 1a Nef when substituted with a glycine (G) by Liu et al. [37] was present at position 124 in subtype C Nef and this mutation was thus named D124G. Codon-optimization entailed changing the codon usage to that utilized by highly expressed human genes as described previously [44] and resulted in a reduction in AT content of approximately 20% for the three genes (data not shown).
In vitro expression of all constructs was assessed by SDS-PAGE of 293-cell lysates and immunoblotting with polyclonal Tat, Rev or Nef-specific mouse serum. As this serum was generated by immunization of mice with plasmid DNA, immunoreactivity of the sera with control Tat and Rev proteins (Aids Research and Reference Reagent Program (ARRRP), NIAID, NIH, Maryland, USA) was assessed before use (data not shown). In addition to anti-Nef mouse serum, lysates from Nef-transfected cells were also blotted with a Nef-specific monoclonal antibody (ARRRP).
All subtype C Tat proteins migrated at a rate corresponding to a molecular weight of approximately 18 kDa and while the codon-optimized plasmids exhibited identical protein expression levels, the wild-type plasmid appeared to yield somewhat lower expression ( Fig. 2A) . A more notable difference in Rev protein expression levels exhibited by the wild-type and codon-optimized rev plasmids was discernable (Fig. 2B) .
openUP -May 2007
In addition, despite identical lengths in amino acid residues, the mutant Rev protein ( 14.5 kDa) migrated more rapidly than the wild-type Rev, which corresponded to 17 kDa. A difference in electrophoretic mobility between the wild-type subtype C Rev protein and the subtype B control protein was also seen. Such variations in electrophoretic mobility on SDS-PAGE gels have been reported for Rev proteins with amino acid differences and the alterations in mobility seen here may thus be due to mutations or subtype-specific differences [33] , [51] and [53] . The transactivation function of the Tat variants was assessed in 293T and HeLa cells by cotransfection with the pLTR-CAT reporter plasmid as previously described [49] and [50] . CAT levels were normalised for transfection efficiency with β-Galactosidase levels and are expressed as percentage native Tat activity (Tat OPT ZA, set to 100%) in Fig. 3 . A previously described Tat-expressing plasmid (SV40-Tat, [50] ) was included as control in The functional ability of Rev-expressing plasmids to mediate nuclear export of RREcontaining pDM128 transcripts was performed in 293T cells as described by Hope et al. [51] . The Rev-expressing plasmid pRSV-Rev was utilised as control and CAT expression exhibited by the wild-type Rev WT ZA plasmid was set as 100% activity. All CAT levels were normalised for transfection efficiency with β-Galactosidase expression levels. While cotransfection with pRSV-Rev and Rev WT ZA induced 85-and 25-fold increases in CAT levels respectively, cotransfection with the Rev mutant Rev M5M10 ZA yielded CAT levels comparable with basal expression recorded in cells transfected with the reporter plasmid only (Fig. 4) . 
Discussion
Sequence analysis of the subtype C consensus sequence that was used to construct the Numerous studies have defined T-cell epitopes with known HLA restriction in virtually all HIV proteins [56] . Although most of these studies were restricted to individuals infected with subtype B viruses, cross-clade sequence conservation and some identification of such epitopes in subtype C sequences makes it possible to map known epitopes onto the vaccine sequences described in this study. Mapping Tat, Rev and Nefspecific epitopes onto the consensus sequences revealed subtype-specific single residue substitutions in Tat and Rev that disrupted most known subtype B epitopes (data not shown), making immunogenicity predictions challenging. These findings illustrate the need for epitope mapping in the regulatory genes of non-B subtypes. However, many
Nef-specific epitopes could be identified in the consensus subtype C Nef sequence, with especially high frequencies of CTL-epitopes in the conserved domains, suggesting Nefresponses to be potentially cross-reactive. These analyses also confirmed that the use of selected single or double mutations to inactivate these proteins do not disrupt epitope sequences [57] . However, the rationale of conserving Nef epitopes by incorporating the G2A and LL174AA mutations was utilized for another Nef vaccine and resulted in decreased immunogenicity in mice [58] , suggesting that the efficacy of this approach will have to be investigated further.
Analysis of the functional activity of Tat revealed that, unlike numerous previous studies demonstrating the inactivity of Tat with a C22G mutation [28] , [29] , [49] and [59] , the subtype C TatC22 was able to activate LTR-directed CAT transcription. The reason for this finding is not clear. Because the assays used in this study were done as those described by Kuppuswamy et al. [49] , who also used the same reporter plasmid and performed the transactivation assays in HeLa cells, the possibility of different
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methodology can be excluded. The importance of cysteine residue conservation at position 22 in Tat is well established. Cys22 is highly conserved among HIV-1 and also a large number of HIV-2 and SIV viruses [60] and with the exception of our work, every previously published experiment has shown that mutation of this residue abrogates transactivation [28] , [29] , [30] , [32] , [49] , [59] , [61] , [62] and [63] . When dissected, only two disparities between these previous experiments and the Tat transactivation work described in this study can be recognized, and both implicate the Tat distinctly different in subtype C viruses when compared to other subtypes [64] , [65] , [66] and [67] . Moreover, while the third variable loop in the Env protein is highly variable in virtually all subtypes, this region was shown to be considerably more conserved in subtype C viruses [68] . Sequence characterization of the subtype C isolates on which our
Tat, Rev and Nef vaccine candidates were based confirmed the presence of these Cspecific signatures in the LTR, Vpu and Rev regions [41] and [42] as well as the conserved nature of the envelope V3 sequences [40] . It would thus not be unreasonable to speculate about the unexplored subtype factor possibly playing a role in a different structure or function of Tat. Notably, in similar studies, when the functionality of the subtype B Tat protein from isolate SF162, which carried the C22 mutation, was determined in 293T cells the results were identical to the subtype C Tat data in this study.
Furthermore, mutation of the C37 residue or mutation of both C22 and C37 in the SF162
Tat brought about abrogation of transactivation activity (zur Megede, unpublished data).
These results point to the equally important possibility that strain-specific variation, rather than subtype-specific variation may affect protein functionality and thus, should be considered for HIV vaccine development. A second distinction between the work completed in this study and again, to our knowledge, all previous studies describing the
Tat22 mutant is the factor of protein length. Most studies investigating the function and structure of Tat22 (and many other studies) were conducted on the 86 amino acid Tat protein from the early laboratory strains that contained a premature truncation in tat exon 2, and not the full-length 101 amino acid Tat that is seen predominantly in wild-type viruses [60] . Yet, early studies showed that the second exon was expendable for transactivation activity [69] . A number of recent studies however, have demonstrated that the second exon, which encompasses 29 amino acids in most strains, enhances viral replication [70] and pathogenesis [71] of HIV-1. The possibility exists that the full length
Tat proteins (subtype C consensus and subtype B SF162) used in this study may not have been inactivated for transactivation activity by mutation of C22 because of a counteracting function of the C-terminal second exon. Interestingly, a Tat mutant (Y26A), which was defective for transactivation activity and viral replication, regained activity when a second-site suppressor mutation (Y47N) was acquired [72] . Thus, we
hypothesise that subtype C viruses may have acquired a mechanism whereby single point mutations involving specific critical cysteine residues may be insufficient to abrogate transactivation activity of Tat. These data certainly provoke consideration of such concepts, but these questions will remain unanswered until they are experimentally defined.
As expected, the mutated consensus Rev construct displayed no functional activity.
Although, no unmutated consensus Rev construct was tested in this study to confirm the abrogation of functionality though mutation of the specific residues, such a consensus Rev protein could be expected to be functionally active as its amino acid sequence reveals no abnormal residue combinations or substitutions in the functional domains [41] .
The relatively lower increase in reporter gene expression (25-fold) by C-clade Rev compared to the published 85-fold increase by B-clade Rev [25] is probably as a result of the considerably lower expression level of the wild-type C-clade Rev.
Similarly to the Tat C22 mutant, mutation of the subtype C Nef myristoylation signal (G2A) and a conserved aspartate at position 124, which was previously shown to be critical for oligomerization, downregulation of CD4 and MHC-I and decreasing viral infectivity [37] , was not sufficient to completely abrogate CD4 downregulation activity.
The finding that the additional substitution of the dileucine motif at position 165 completely disrupts CD4 downregulation confirms the critical importance of this motif for the CD4-downregulation activity of Nef [38] and [73] . The reason for this discrepancy in functional activity of an unmyristoylated subtype C Nef carrying the D124G mutation, with previous data that demonstrated such mutations to sufficiently inactivate subtype B Nef, is unclear. As we used the same methodologies that have been used to demonstrate these findings for subtype B Nef [52] and [57] , methodology can be eliminated as possible cause. Again, the major differences between our Nef constructs and those studied previously are the subtype and viral strain. These discrepant results makes it reasonable to express concern about the belief that inactivation of such regulatory proteins through site-specific mutations is conserved across all viral strains and subtypes.
The codon-optimization of the different reading frames had variable effects on the expression rates of the proteins. Besides mRNA stability, which is the major factor influenced by codon-optimization, many factors such as protein stability and length, nucleotide and amino acid composition contribute towards protein expression rates and half-lives. The mechanisms behind these differing influences on expression require further investigation.
Vaccination of mice with plasmid DNA encoding either wild-type or codon-optimized, mutated, consensus Tat, Rev and Nef proteins was performed to assess the potential immunogenicity of these constructs. Immunoblotted Tat, Rev and Nef proteins were immunoreactive with serum from immunized CB6F1 mice and antigen-specific T lymphocyte responses were generated in BALB/c mice. These results demonstrate successful expression and antigen presentation of these plasmid constructs in the murine model. Codon-optimization of these genes appeared to have made no marked difference in the immunogenicity of the single-gene Rev and Nef constructs. However, there was a markedly increased T lymphocyte response in mice that received the codon-optimized
Tat compared to those that received the wild-type. Notably, the use of consensus protein sequences carrying the respective inactivating mutations did not significantly diminish the immunogenicity of the codon-optimized proteins.
It should be noted that the peptide pools used for splenocyte stimulation in the intracellular cytokine assays were derived from HIV-1 subtype C strain Du151 
